PCDH9: A Potential Drug Target and Biomarker for Diseases (G5101)

Target Name: PCDH9

NCBI ID: G5101

PCDH9

PCDH9: A Potential Drug Target and Biomarker for Diseases

PCDH9 (PCDH9 variant 1) is a gene that encodes for a protein known as protamine C (P-type Ca2+-ATPase), which is a key enzyme involved in the regulation of intracellular calcium levels. The PCDH9 gene has been identified as a potential drug target and a biomarker for various diseases, including heart disease, diabetes, and neurodegenerative disorders.

The PCDH9 gene was first identified in 2008 as a potential gene that could serve as a therapeutic target for diseases that involve the regulation of intracellular calcium levels. This was based on the fact that the PCDH9 gene encodes for a protein that is involved in the regulation of the levels of calcium ions in cells, and that mutations in the PCDH9 gene have been linked to a range of diseases.

Since its initial identification, several studies have further confirmed the potential of PCDH9 as a drug target and biomarker. For example, studies have shown that PCDH9 mutations are associated with increased risk of developing cardiovascular disease, including heart failure, hypertension, and stroke. Additionally, studies have also shown that PCDH9 mutations are associated with increased risk of developing neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease.

In addition to its potential as a drug target, PCDH9 has also been identified as a potential biomarker for a range of diseases. For example, studies have shown that PCDH9 mutations are associated with increased levels of reactive oxygen species (ROS) in cells, which can damage cellular components and contribute to the development of a range of diseases. Additionally, studies have also shown that PCDH9 mutations are associated with decreased levels of a protein called superoxide dismutase (SOD), which is involved in the regulation of oxidative stress in cells.

Despite the potential benefits of PCDH9 as a drug target and biomarker, further research is needed to fully understand its role in the development and progression of disease. For example, it is still not clear how PCDH9 mutations contribute to the development of specific diseases, or how targeting PCDH9 with drugs or other therapeutic approaches might be effective in treating these diseases.

In conclusion, PCDH9 is a gene that has the potential to serve as a drug target and biomarker for a range of diseases. Its role in the regulation of intracellular calcium levels and its association with the development of various diseases make it an attractive target for researchers to investigate further. Further studies are needed to fully understand its role in the development and progression of disease, and to identify effective ways to target PCDH9 with drugs or other therapeutic approaches.

Protein Name: Protocadherin 9

Functions: Potential calcium-dependent cell-adhesion protein

The "PCDH9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PCDH9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets